Abstract:It is possible to repress amyloid precursor protein (APP) mRNA translation as a novel anti-amyloid pharmacotherapy for Alzheimer's Disease (AD). This therapeutic model is consistent with well-documented cases where AD pathology can be the genetic consequence of duplications of the APP gene. This genetic duplication caused increased brain APP dose leading to over-expression of Ab amyloid and then disease onset. These findings support our pharmacological goal to reduce APP expression. As due diligence, we showed that FDA drugs (i.e., paroxetine & N-acetyl cysteine) selectively reduced APP translation in neural and epithelial cells while maintaining compensatory APLP-1/-2 levels, but then these drugs also limited Aß production in vivo. Paroxetineis a well-known selective serotonin reuptake inhibitor (SSRI) and a clinical anti-depressant that was identified to inhibit APP 5'untranslated region (5'UTR)-luciferase reporter expression. We showed proof-of-concept that unlike other SSRIs, paroxetine exhibits a planar tricyclic aromatic benzodioxole structure and provided anti-amyloid activity in the brains of APP(Swe) transgenic mice. Additionally, posiphen, a + enantiomer of the well-tested anti-cholinesterase phenserine, passed phase I clinical trials for AD as an APP 5'UTR inhibitor. Encouraged by this, we screened the 110,000 compound molecular library at Harvard's Laboratory for Drug Discovery in Neurodegenerative Diseases that had been optimized to obtain pharmacologically favorable activity agents; for example small molecules that inhibit mesangial cell proliferation following three-dimensional pharmacophore modeling. From our screen, thirteen top leads shared chemical features pertinent to their potently blocking APP 5'UTR directed translation (IC-50: 1nM to ∼100nM). This correlated well with their selective suppression of APP expression in several neural cell lines. The top compounds of these APP 5'UTR inhibitors were 50-fold more potent blockers of Aß precursor translation than either paroxetineor posiphen. The most active lead was the ninth compound in the series, APP blocker-9 (“JTR-009”). Critically, JTR-009 effectively reduced APP levels in primary mouse E-18 cortical neurons at single nanomolar concentrations similar to that for the serum concentrations of effective clinical drugs. Our top APP translation blocker, JTR-009, is a planar tricyclic benzimidazole that could potentially intercalate into the single 146 base APP 5'UTR specific RNA stem loop. Confirming specificity, we are checking how JTR-009 blocks ribosome scanning of the APP 5'UTR to impede translation (Aß output) but not to interact with the 5'UTRs of APP-like protein (APLP-1/-2) mRNAs. We are currently determining the in vivo pharmacokinetics and tolerance of JTR-009, and we are completing a structure activity relationship (SAR) study of ten close analogs using primary cortical neurons from the B6-R1.40 genomic mouse model of AD.

RNA Therapeutics Directed to the Non Coding Regions of APP Mrna, in Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl Cysteine.

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

P2‐497: Mechanism of Action of App Translation Blockers: from Model to Human

Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol

[P‐199]: Alzheimer's Disease Drug Discovery Targeted to the APP Mrna 5′ Untranslated Region, Paroxetine Proof‐of‐concept for a Validated Target

Specific APP translation blockers as a therapeutic intervention for Alzheimer's disease

Therapeutic Action of Translation Blockers on Expression of the Amyloid Precursor Protein As a Central Ferroxidase

Cattle Encephalon Glycoside and Ignotin Ameliorate Palmitoylation of PSD-95 and Enhance Expression of Synaptic Proteins in the Frontal Cortex of a APPswe/PS1dE9 Mouse Model of Alzheimer's Disease

Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease

Novel 5 ' Untranslated Region Directed Blockers of Iron-Regulatory Protein-1 Dependent Amyloid Precursor Protein Translation: Implications for Down Syndrome and Alzheimer'S Disease

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Memory impairments in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A‐484954

An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease

Intranasal Delivery of 9-Cis Retinoic Acid Reduces Beta-Amyloid Deposition Via Inhibiting Astrocyte-Mediated Inflammation

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

EK100 and Antrodin C Improve Brain Amyloid Pathology in APP/PS1 Transgenic Mice by Promoting Microglial and Perivascular Clearance Pathways

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease

Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP swe /PS1 ΔE9 transgenic mice for the diagnosis of Alzheimer's disease.